Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) issued an update on its FY13 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $6.30-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.33, AmericanBankingNews.com reports.
Several analysts have recently commented on the stock. Analysts at Barclays raised their price target on shares of Jazz Pharmaceuticals Plc from $112.00 to $130.00 in a research note to investors on Monday, November 25th. They now have an overweight rating on the stock. On a related note, analysts at FBR Capital Markets reiterated an outperform rating on shares of Jazz Pharmaceuticals Plc in a research note to investors on Monday, November 25th. They now have a $198.00 price target on the stock, up previously from $105.00. Finally, analysts at R. F. Lafferty raised their price target on shares of Jazz Pharmaceuticals Plc from $102.00 to $118.00 in a research note to investors on Wednesday, November 13th. They now have a buy rating on the stock. Sixteen analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average price target of $102.59.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) opened at 113.81 on Wednesday. Jazz Pharmaceuticals Plc has a 52 week low of $48.71 and a 52 week high of $118.80. The stock has a 50-day moving average of $99.83 and a 200-day moving average of $83.10. The company has a market cap of $6.577 billion and a price-to-earnings ratio of 20.01.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last announced its earnings results on Tuesday, November 5th. The company reported $1.78 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter last year, the company posted $1.29 earnings per share. Jazz Pharmaceuticals Plc’s revenue was up 32.3% compared to the same quarter last year. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.